The drugs best known for dramatic weight loss are quietly becoming a flashpoint in the competition for talent, and employers who have been slow to act on coverage may be running out of time.
According to NFP’s (an Aon company) 2026 U.S. Benefits Trend Report, nearly one-third of employees say they would switch employers to gain access to GLP-1 coverage, elevating these medications from a line item in the pharmacy budget to a workforce strategy problem.
At the same time, 51% of employers now cite GLP-1 diabetes and weight-loss medications as the top driver of prescription drug spend, surpassing oncology and autoimmune treatments.
The result is a strategic bind. Employers cannot easily afford to cover these drugs broadly, and they increasingly cannot afford not to.
Two tiers of GLP-1 coverage
The NFP report describes a market that has effectively split in two: GLP-1 coverage for diabetes, where clinical justification is clearer, and coverage for weight management, where employer decisions vary dramatically and cost-benefit calculations remain unsettled.
Some employers have been reluctant to extend coverage to the weight-loss indication. Coverage for obesity drugs, including GLP‑1 medications, rose to 44% of large employers (500+ employees) in 2024, and 64% of the largest employers (20,000+ employees) now offer this coverage, according to data from Mercer.
Pharmacy benefit managers make it relatively easy to toggle that coverage distinction on or off, and a good number have done so. But employee expectations, shaped by the cultural ubiquity of drugs like Ozempic and Wegovy, have not followed suit.
Employee satisfaction with prescription cost-sharing reflects the tension. The NFP report found satisfaction dropped from 73% to 66% year over year, and 47% of employees now use websites or apps to find lower drug prices. HR leaders can take this as a signal that out-of-pocket costs are becoming unattractive for many workers.
Read more | Exploding GLP-1 costs: How employers are scrambling to manage
New GLP-1 models emerge, but tradeoffs remain
The market is beginning to respond. CVS Caremark recently announced a collaboration with telehealth company eMed that allows eligible employees to purchase GLP-1s online with wraparound clinical support, including weekly check-ins, side effect management and biannual blood testing. Employers can determine how much of the cost to subsidize, offering a middle path between full formulary coverage and nothing at all.
Aon, which piloted a similar eMed program for its own employees, reported that participants stayed on the medication longer and saw meaningful improvements in weight and BMI. About 9% of eligible Aon employees enrolled, according to reporting in Axios.
Still, the economics are unresolved. Research from the Employee Benefit Research Institute estimates that adding GLP-1 coverage for weight loss could increase employer health insurance premiums by between 5.3% and 13.8%, depending on eligibility criteria and adherence patterns. Any downstream savings from improved health outcomes, meanwhile, may take years to materialize.
Despite the prospect of waiting for long-term, health-driven premium savings, the NFP data suggests that doing nothing carries its own cost. With nearly a third of employees willing to change jobs over this benefit, GLP-1 coverage is no longer a clinical decision delegated to the benefits team. It is a total rewards decision that belongs in conversations about talent competitiveness.
Hybrid models like the eMed partnership may offer employers a way to act without fully absorbing the cost, but the window for a measured response is narrowing as employee expectations continue to rise.
Credit: Source link
